21-07-2025
Sarepta's Elevidys Halted at Children's Hospital Los Angeles
By and John Tozzi
Save
Children's Hospital Los Angeles paused the use of Sarepta Therapeutics Inc. 's gene therapy for Duchenne muscular dystrophy in the wake of rising safety concerns about liver toxicity, adding to mounting challenges for the drugmaker.
The leading children's hospital said it halted the treatments effective July 18, the same day the Food and Drug Administration requested that Sarepta stop distributing the drug, Elevidys. Sarepta has refused to stop shipments.
